Cointime update: China’s National Medical Products Administration approved ruifexibart injection (subcutaneous), marketed as Aiqingda, from Beijing Shengdi Pharmaceutical, for adults and adolescents aged 12 and older with homozygous familial hypercholesterolemia (HoFH). The drug, cleared under the priority review pathway, is used alongside a low-fat diet and other lipid-lowering therapies to reduce LDL-C levels, offering patients a new treatment option.
China NMPA Approves Ruifexibart Subcutaneous Injection for HoFH
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
Dow Falls 1% as US Stocks Extend Losses
5h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
5h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
5h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal
7h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
7h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion